Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
Subscribe To Our Newsletter & Stay Updated
